This two-day conference will serve as a platform to discuss compliance and transparency areas of key concern. Goal is to unravel compliance challenges, define and learn fair market value and develop a consistent, simple and transparent method and strategy for your company.
How to manage deviations in the most effective way
Eugenio Filippi is Senior Manager of the European Plasma Logistics and Dispositioning Center at BAXTER. He has already spoken at the Cold Chain online conference in August 2015.
Now Eugenio will present his case study "How to manage process deviations and showcase your data" at this Quality Assurance Pharma & Biotech online conference. As a short preview, we have asked Eugenio a few questions regarding his current topic:
Are pharma companies paying close enough attention to deviations?
Yes, for sure they are, the big question is whether they are doing so in the most effective way.
What are the basic steps in deviation management?
Most Quality Organizations are very focused on root cause analysis and defining corrective and preventive actions (CAPAs). I would argue that unless the data is gathered and analyzed correctly, this might not really bring the expected benefits. If your trending analysis never shows you any issues, are you looking at the right data?
How can we expect or predict particular deviations?
Generally speaking, wherever manual intervention is present in a process, you will sooner or later have human errors. Might not happen very often, but given equal opportunities for failure, it will happen. The fact that you have been lucky so far does not make your process robust forever.
What are the most common mistakes in deviation management?
Blaming your employees for their mistakes. You should be addressing the flawed process that has allowed them to make that mistake, and with their input, change it to eliminate those situations. A classic example is that you cannot start an automatic transmission car unless your foot is on the brake. This eliminates the situation of the user forgetting to engage the brake and possibly hitting a wall. Blaming them afterwards might be very costly.
Interested in this topic?
Project & Portfolio Management for Pharma and Biotech – EAST
For the upcoming Project and Portfolio Management for Pharma and Biotech Conference, Fleming presents a high-level meeting building on more than a decade of experience in running global Pharma PPM events worldwide.
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?
With improved patient engagement to increased patient adherence
Chronic illnesses are commonly treated with the long-term use of medications. This treatment could be successful, however, its benefits are overshadowed by the fact that 50% of patients don't take their medications as prescribed. Reveal all the alarming numbers of non-adherence and learn how to decrease it with improved patient engagement.
The expanding role of pharmacovigilance and risk management
A profound and accelerated transformation of the Pharmacovigilance world is happening, due to several key drivers. The absolute necessity to ensure that patients can benefit from an early access to new drugs, while ensuring an optimal identification and management of risks is vital.